Amgens horizon acquired fusion protein eases sjogrens severity ph 3 win

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.

science

Sources

• T2Amgens horizon acquired fusion protein eases sjogrens severity ph 3 winFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 12:07